1 / 1
High-Quality Semax Peptide CAS 80714-61-0 - Premier China Suppliers & Factory for CNS Health Solutions Manufacturer, Pricelist
Product Description
Semax is a synthetic peptide drug derived from a fragment of adrenocorticotropic hormone (ACTH). It was initially developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike its parent hormone ACTH, which primarily affects the adrenal glands, Semax removes hormonal activity but retains and significantly enhances its potent effects on the central nervous system.
Therapeutic Areas
Semax shows great therapeutic potential primarily in the fields of neuroscience and psychiatry.
Stroke (ischemic)
This is the main indication for which Semax has been approved in Russia. It is used in the acute and recovery phases to limit the infarct area, protect dying neurons, and promote functional recovery.
Cognitive impairment
Used to treat vascular and post-traumatic cognitive impairment, it can improve memory, attention and psychological performance.
Anxiety and depressive disorders
As an adjunct therapy, especially effective for depressive states associated with burnout and cognitive decline.
Neurodegenerative diseases
Its potential for use in Alzheimer's and Parkinson's diseases is being investigated, primarily based on its neurotrophic and protective effects.
Optic neuropathy
Used to treat optic nerve damage and atrophy caused by diseases such as glaucoma.
"Cognitive enhancement" in healthy individuals
In some regions (for non-medical purposes), it is used as a "nootropic" to enhance learning, memory, and mental concentration under stress.
Outlook & Development
Semax has a promising future, but it also faces some challenges:
Prospects and Opportunities:
Expanding indications
The greatest potential lies in its application to a wider range of neurodegenerative diseases. Preclinical and clinical studies are underway for Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Combination therapy
Semax may be used in combination with other neuroprotective agents or rehabilitation therapies to produce a synergistic effect and enhance treatment outcomes.
Development of novel analogues
Researchers are developing analogues that are more potent and have a longer duration of action than Semax (e.g., Selank is used for anxiety, and Adamamax is a more stable version of Semax).
Global market expansion
Currently, Semax is mainly used in Russia and some Eastern European countries. If it can pass rigorous clinical trials and obtain regulatory approval (such as FDA approval) in developed Western countries (such as the United States and the European Union), it will greatly promote its global application.
Challenges and Future Development:
Rigorous clinical validation
Although there has been extensive research in the former Soviet Union, its efficacy and safety still need to be confirmed through large-scale clinical trials that meet international standards (such as randomized, double-blind, placebo-controlled trials) to meet the requirements of regulatory agencies such as the FDA and EMA.
Precise elucidation of the mechanism of action
Although there is a basic understanding of its mechanism, more precise molecular pathways still need to be explored.
Commercialization and awareness
Globally, Semax has far lower awareness than traditional neurological drugs, requiring extensive market education and commercial promotion.
Frequently Asked Questions (FAQ)
What is Semax and where was it developed?
Semax is a synthetic peptide drug derived from a fragment of adrenocorticotropic hormone (ACTH). It was initially developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences.
How does Semax differ from its parent hormone ACTH?
Unlike ACTH, which primarily affects the adrenal glands, Semax has its hormonal activity removed. However, it retains and significantly enhances potent effects on the central nervous system.
What are the primary therapeutic uses for Semax?
Semax is primarily used in neuroscience and psychiatry. Its main approved indication in Russia is for ischemic stroke, but it is also used for cognitive impairment, anxiety and depressive disorders, and optic neuropathy.
Can healthy individuals use Semax?
In some regions, Semax is used for non-medical purposes as a "nootropic" by healthy individuals aiming for cognitive enhancement, helping to improve learning, memory, and mental concentration under stress.
What is the future outlook for Semax?
The future looks promising with prospects for expanding indications into neurodegenerative diseases (like Alzheimer's and Parkinson's), utilizing combination therapies, developing novel analogues like Adamamax, and expanding into the global market.
What challenges does Semax face in the global market?
To be widely accepted globally, Semax needs rigorous large-scale clinical trials that meet international standards (FDA and EMA requirements), a more precise elucidation of its molecular pathways, and extensive market education to overcome low global awareness.
